Oscar Health (NYSE:OSCR)报告季度每股亏损$(0.62)，低于分析师共识预期的$(0.58)，差距为6.9%。与去年同期每股亏损$(0.66)相比，这是6.06%的改善。该公司报告季度销售额为$23.9亿，低于分析师共识预期的$24.7亿，差距为3.35%。与去年同期的$14.3亿相比，这是67.04%的增长。
以上内容来自Benzinga Earnings专栏，原文如下：
Oscar Health (NYSE:OSCR) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 6.06 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $2.39 billion which missed the analyst consensus estimate of $2.47 billion by 3.35 percent. This is a 67.04 percent increase over sales of $1.43 billion the same period last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.